Hbw Advisory Services 13F: Adds $1.1M to Amgen (AMGN) Stake
Hbw Advisory Services expanded its stake in Amgen Inc. by 122.3%, bringing its total holdings to 4,746 shares.
Reviewed by automated data checks against the source filing. How we make and check alerts
Hbw Advisory Services added 2,611 shares to its stake in Amgen Inc. ($AMGN), a 122.30% increase, according to a 13F filing with the SEC dated October 15, 2026. It reported 4,746 shares worth $2 million at the end of the quarter.
Since the filing, $AMGN is down 0.3% to date (from the $434.03 close on Oct 15, 2026).
Find the original: Hbw Advisory Services 13F filings on SEC EDGAR
AMGN
Amgen Inc.
Key Points
- Hbw Advisory Services grew its Amgen Inc. position by 122.3% during the period, adding 2,611 shares to reach a total of 4,746 shares worth about $2.0 million.
- Amgen Inc. trades near its 52-week high with a market capitalization of $234.7 billion and a P/E ratio of 27.0, while heading toward its next earnings report on November 3, 2026.
- Major financial institutions adjusted their positions as well, with Blackrock Inc. increasing its stake by 4.8% to hold 49,362,016 shares valued at $21.4 billion.
Get $AMGN trade alerts by text
We text you when insiders, Congress or big funds trade $AMGN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Amgen Inc. alert may contain errors. Disclosures
Hbw Advisory Services filed a Form 13F with the Securities and Exchange Commission reporting a major expansion in its investment in Amgen Inc. AMGN, boosting its stake by 122.3% during the reporting period. The firm bought an additional 2,611 shares, bringing its total ownership to 4,746 shares. Based on market prices, the updated position carried a reported value of about $2.0 million. Institutional 13F filings look backward at holdings from the end of the reporting quarter and do not necessarily reflect current trading activity today.
Hbw Advisory Services vs. the S&P 500
Hypothetical returns from Hbw Advisory Services's disclosed trades, not real profit or advice. How we model this.
What Changed in Hbw Advisory Services's Amgen Position
Prior to this adjustment, Hbw Advisory Services held 2,135 shares of the biotechnology firm. By acquiring 2,611 more shares, the firm more than doubled its stake in Amgen Inc. to 4,746 shares. Institutional filings like this one provide a look at portfolio adjustments made by professional money managers during the period.
Other Institutional Activity in Amgen
Blackrock Inc. grew its holdings by 2,260,856 shares, ending with 49,362,016 shares worth about $21.4 billion following a 4.8% increase. Vanguard Capital Management LLC grew its holdings by 234,604 shares, ending with 35,250,101 shares worth about $15.3 billion following a 0.7% increase. State Street Corporation grew its holdings by 12,219 shares, ending with 30,560,537 shares worth about $13.2 billion following a 0.0% increase. Capital World Investors cut its holdings by 213,811 shares, ending with 29,075,329 shares worth about $12.6 billion following a -0.7% decrease. Invesco Ltd. grew its holdings by 435,254 shares, ending with 16,320,446 shares worth about $7.1 billion following a 2.7% increase.
Amgen Inc. Stock Up 1.4%
Amgen shares recently changed hands around $433.04, resting comfortably above the 200-day moving average of $368.38 and higher than the 50-day moving average of $414.46. The stock sits near its 52-week high of $447.03, with a 52-week low sitting at $288.00. The company carries a market capitalization of $234.65 billion, a P/E ratio of 26.96, and a forward P/E of 17.71.
Recent Earnings
Amgen reported $38.1 billion in revenue over the trailing period, alongside a revenue growth rate of 9.5%. Earnings per share registered at $16.10, backed by a net margin of 22.95% and a return on equity of 91.47%. The company's next earnings report is scheduled for November 3, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 6.1%. Revenue missed estimates by 1.5%.
-
Profit surprise
EBITDA missed by 45 percent. Operating income missed by 28 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
1 target raise, 2 target cuts.
-
Earnings quality
Gross margin up 4.6 points. Operating margin up 16.5 points. Positive free cash flow.
Earnings Call Summary
Amgen had a strong first quarter with earnings per share of 5.15 dollars beating expectations of 4.73 dollars. Six key medicines grew sales by 24 percent year over year and now make up 70 percent of total sales. The obesity drug Meritide is advancing well in late-stage testing with new studies showing better tolerance when patients take it less frequently, potentially every eight to twelve weeks instead of weekly injections.
Guidance Amgen raised its 2026 outlook to revenue between 37.1 billion and 38.5 billion dollars, and earnings per share between 21.70 and 23.10 dollars. The company expects its fast-growing medicines like Repatha and Evenity to offset patent losses. Management said capital spending will remain at about 2.6 billion dollars to scale manufacturing for new drug launches.
Clearly negative report. The company missed important expectations and likely triggers downward revisions.
Dividend
Amgen pays an annual dividend yield of 2.32%, supported by a payout ratio of 60.87%.
Insider Buying and Selling at Amgen Inc.
Khosla Rachna sold 3,252 shares of Amgen stock on August 13, 2026, in a transaction valued at $1,346,499.00. Grygiel Nancy A sold 2,970 shares of Amgen stock on August 6, 2026, at an average price of $402.16, for a total value of $1,194,415.00. Miller Derek sold 3,890 shares of Amgen stock on August 6, 2026, at an average price of $402.54, for a total value of $1,565,898.00.
Analysts Set New Price Targets
On October 13, 2026, Guggenheim maintained a Neutral rating on the stock while adjusting its price target from $388.00 to $378.00. On October 12, 2026, BMO Capital maintained a Market Perform rating on the stock while adjusting its price target from $450.00 to $415.00. On October 12, 2026, Wells Fargo maintained an Equal-Weight rating on the stock while adjusting its price target from $435.00 to $430.00. On October 9, 2026, UBS maintained a Buy rating on the stock while adjusting its price target from $430.00 to $470.00. On October 8, 2026, RBC Capital maintained an Outperform rating on the stock while adjusting its price target from $400.00 to $430.00. Across the broader analyst community, Amgen holds a consensus recommendation of hold and a mean price target of $394.98 based on 29 analyst opinions.
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Operating within the healthcare sector, the drug manufacturer focuses on developing advanced treatments for serious illnesses. Institutional investments from firms like Hbw Advisory Services highlight ongoing portfolio adjustments as the company approaches its next quarterly update.
Bottom Line
Investors are keeping an eye on Amgen ahead of its upcoming earnings release scheduled for November 3, 2026. This 13F filing captures portfolio positioning from a prior period and should be reviewed alongside more recent market data.
Related Filing Alerts
Source: Hbw Advisory Services's 13F filing on $AMGN (Oct 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Hbw Advisory Services 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts